![Lisata Therapeutics Inc](/common/images/company/N_LSTA.png)
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to BOLSTER trial BASKING RIDGE, N.J., July 16...
BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (βLisataβ or the βCompanyβ), a clinical-stage pharmaceutical company developing innovative...
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024...
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (βLisataβ or the βCompanyβ), a clinical-stage pharmaceutical company developing innovative...
Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024...
Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.25 | 7.33137829912 | 3.41 | 3.83 | 3.3171 | 18558 | 3.63257913 | CS |
4 | 0.36 | 10.9090909091 | 3.3 | 3.83 | 3.22 | 17558 | 3.50946384 | CS |
12 | 0.9 | 32.6086956522 | 2.76 | 3.83 | 2.51 | 16787 | 3.30081584 | CS |
26 | 0.74 | 25.3424657534 | 2.92 | 3.83 | 2.42 | 14627 | 3.18632503 | CS |
52 | -0.04 | -1.08108108108 | 3.7 | 3.8699 | 1.95 | 19900 | 2.80954696 | CS |
156 | -5.14 | -58.4090909091 | 8.8 | 9.38 | 1.95 | 23488 | 3.85133116 | CS |
260 | -5.14 | -58.4090909091 | 8.8 | 9.38 | 1.95 | 23488 | 3.85133116 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.